Difference between revisions of "IL21R-AS1"
| Line 1: | Line 1: | ||
==Annotated Information== | ==Annotated Information== | ||
===Approved Symbol=== | ===Approved Symbol=== | ||
| − | IL21R-AS1 | + | IL21R-AS1 (IL21R antisense RNA 1) |
| − | |||
| − | IL21R antisense RNA 1 | ||
| − | |||
| − | |||
| − | |||
| − | |||
===Chromosome=== | ===Chromosome=== | ||
16p12.1 | 16p12.1 | ||
===RefSeq ID=== | ===RefSeq ID=== | ||
| − | |||
| − | |||
| − | |||
| − | |||
NR_037158 | NR_037158 | ||
===pubmed IDs=== | ===pubmed IDs=== | ||
26857419 | 26857419 | ||
| + | ===Expression=== | ||
| + | qPCR analysis shows that IL21R-AS1 is 2.212-fold up-regulated in CAD (coronary artery disease) patients.<ref name="ref1"> | ||
| + | [[File:Expression levels of CoroMarker, IL21R-AS1, BAT5, AC107016.1, and RP11-203B9.4 were quantified by qPCR in the PBMCs of CAD patients (n = 15) and control subjects (n = 15) (*P< 0.05 vs. control).jpg|right|thumb|300px|'''Expression levels of CoroMarker, IL21R-AS1, BAT5, AC107016.1, and RP11-203B9.4 were quantified by qPCR in the PBMCs of CAD patients (n = 15) and control subjects (n = 15) (*P< 0.05 vs. control).'''<ref name="ref1" />]] | ||
| + | |||
===Disease=== | ===Disease=== | ||
| − | coronary artery disease | + | coronary artery disease <ref name="ref1" /> |
| + | |||
| + | ==Labs working on this lncRNA== | ||
| + | * Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, P.R. China. | ||
| + | * Chongqing Institute of Cardiology, Chongqing, P.R. China. | ||
| + | |||
| + | ==References== | ||
| + | <references> | ||
| + | <ref name="ref1"> | ||
| + | </ref>(1) | ||
| + | </references> | ||
Revision as of 07:25, 15 October 2017
Contents
Annotated Information
Approved Symbol
IL21R-AS1 (IL21R antisense RNA 1)
Chromosome
16p12.1
RefSeq ID
NR_037158
pubmed IDs
26857419
Expression
qPCR analysis shows that IL21R-AS1 is 2.212-fold up-regulated in CAD (coronary artery disease) patients.Cite error: Closing </ref> missing for <ref> tag(1)
</references>
